NXTC FY 2020 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+252.6% YoY

Gross Profit

-$24M-108.0% margin

Operating Income

-$41M-184.2% margin

Net Income

-$37M-163.6% margin

EPS (Diluted)

$-15.95

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$52M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$307M

Total Liabilities

$13M

Stockholders' Equity

$294M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$6M	+252.6%
Gross Profit	-$24M	-$28M	+13.3%
Operating Income	-$41M	-$37M	-10.0%
Net Income	-$37M	-$34M	-8.5%